PaxMedica Overview

PaxMedica Research & Development

Research & Development expenses for PXMD.

Quarterly R&D Expenses

$1.51M

↑ 156.27% YoY

As of Jun 30, 2024

Annual R&D Expenses (TTM)

$5.01M

↑ 263.56% YoY

Trailing 12 months ending Jun 30, 2024

Average R&D Expenses (Comparison Companies)

Research & Development History

Research & Development Comparison

Annual Research & Development Growth Rate (%)

Annual Research & Development Growth (Absolute)

Jump to metric

Total Revenue Cost of Revenue Gross Profit Research & Development Selling, General & Admin Operating Income Other Income Expense Net EBIT Income Tax Net Income Profit Margin